M42, the AI-driven global health powerhouse, has appointed Dimitris Moulavasilis as its new Group Chief Executive Officer, effective immediately. The leadership transition comes as Hasan Jasem Al Nowais, who has played a pivotal role in shaping M42’s remarkable growth story, steps down from executive leadership to continue serving on the company’s Board.
Mr. Moulavasilis steps into the role with deep roots in the M42 ecosystem and an impressive global track record. He has been at the helm of M42’s Global Patient Care platform, a key pillar of the company’s mission to reimagine healthcare worldwide, and previously led Diaverum, a global renal care provider acquired by M42 in 2023. His earlier role as Group CEO of Affidea, a major European provider of imaging, outpatient, and oncology services, adds to his rich experience in leading complex healthcare operations.
This leadership transition represents not only a seamless handover but also a strategic continuation of M42’s ambitious journey. Mr. Moulavasilis brings with him a blend of operational acumen, digital transformation expertise, and a forward-thinking vision that is perfectly aligned with M42’s global aspirations.
His appointment follows an extraordinary tenure by Mr. Al Nowais, who spearheaded the transformation of Mubadala Health and later led the historic merger with G42 Healthcare that gave birth to M42 in 2022. Under his leadership, M42 expanded into 26 countries, achieved fivefold growth in just seven years, and set new benchmarks in patient care through a mix of acquisitions, partnerships, and innovative strategies.
Peng Xiao, Chairman of M42 and Group CEO of G42, shared his appreciation for Mr. Al Nowais’ transformative leadership, noting:
“Building on the strong foundation established by Hasan, we are now entering the next chapter of M42’s journey… His appointment marks an exciting new phase for M42 as we continue to advance the frontiers of healthcare through technology and world-class clinical excellence.”
Looking ahead, Mr. Moulavasilis is set to lead the company into its next phase of innovation and global expansion.
“It is a privilege to be entrusted with writing the next chapter for M42,” he said. “Together with our people, partners and patients, we will continue to push the boundaries of healthcare innovation… and positively impact lives locally and globally.”
As M42 embarks on this next era, Mr. Al Nowais expressed full confidence in the company’s future.
“I am confident that Dimitris will continue to drive this vision forward with the same passion, purpose and relentless pursuit of excellence… I look forward to supporting Dimitris’ efforts and M42 as a member of its Board.”
